Davis Polk advised the underwriters in connection with an initial public offering of 6,666,667 shares of common stock of NGM Biopharmaceuticals, Inc. at $16.00 per share,…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Ambrogio Visconti
…
This content is for Standard 1 Year members only. LoginJoin Now